Search Result

Results for "

cyclic phosphodiesterase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Phosphodiesterase (PDE) (99) Adenosine Deaminase (3) Adenosine Receptor (4) Adenylate Cyclase (2) Adrenergic Receptor (2) Antibiotic (1) Apoptosis (9) Bacterial (4) Biochemical Assay Reagents (1) Calcium Channel (5) Calmodulin (2) Carbonic Anhydrase (1) Drug Metabolite (1) Endogenous Metabolite (19) Fungal (1) Glucosylceramide Synthase (GCS) (1) Guanylate Cyclase (1) Histamine Receptor (1) Influenza Virus (3) Interleukin Related (1) Isotope-Labeled Compounds (10) mAChR (1) NO Synthase (5) Nucleoside Antimetabolite/Analog (1) Parasite (1) PKA (5) PKC (1) PKG (3) Potassium Channel (3) Reference Standards (16) TNF Receptor (5)
By Research Areas:	Cancer (22) Cardiovascular Disease (39) Endocrinology (18) Infection (10) Inflammation/Immunology (43) Metabolic Disease (17) Neurological Disease (26)
Oligonucleotides:	Nucleotide Analogs (1)

118

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: Phosphodiesterase (PDE) HCN Channel Cyclic GMP-AMP Synthase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12085

Apremilast 5+ Cited Publications CC-10004	Phosphodiesterase (PDE) Apoptosis TNF Receptor	Inflammation/Immunology
Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC₅₀ of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC₅₀ of 104 nM .

HY-B0442

Vardenafil 5 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0763

Ibudilast Maximum Cited Publications 10 Publications Verification KC-404; AV-411; MN-166	Phosphodiesterase (PDE)	Inflammation/Immunology Cancer
Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .

HY-18252

Avanafil 1 Publications Verification TA1790	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-B0128

Diphylline 1 Publications Verification Diprophylline	Adenosine Receptor Phosphodiesterase (PDE)	Cardiovascular Disease Inflammation/Immunology
Diphylline (Diprophylline) is a potent A1/A2 adenosine receptor antagonist and cyclic nucleotide *phosphodiesterase* inhibitor. Diphylline, a xanthine derivative, is a bronchodilator and vasodilator agent and has the potential for chronic bronchitis and emphysema .

HY-B0442A

Vardenafil hydrochloride 5 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil hydrochloride is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B1294

Amrinone Inamrinone	Phosphodiesterase (PDE)	Cardiovascular Disease
Amrinone (Inamrinone) is a positive inotropic-vasodilator agent. Amrinone is a selective phosphodiesterase III inhibitor that increases cyclic adenosine monophosphate by preventing its breakdown. Amrinone is also an orally active, non-glycosidic and non-catecholamine cardiotonic agent .

HY-111673

8-CPT-Cyclic AMP sodium 8-CPT-cAMP sodium; 8-(p-Chlorophenylthio)-cAMP sodium	PKA Phosphodiesterase (PDE)	Inflammation/Immunology
8-CPT-Cyclic AMP (8-CPT-cAMP) sodium is a selective activator of cyclic AMP-dependent protein kinase (PKA). 8-CPT-Cyclic AMP sodium is also a potent inhibitor of the cyclic GMP-specific phosphodiesterase (PDE VA) with an IC₅₀ of 0.9 μM. 8-CPT-Cyclic AMP sodium also inhibits PDE III and PDE IV with IC₅₀Cyclic AMP sodium is a very high affinity for Epac and is a potent Epac activator .

HY-163285

PDE3B-IN-1	Phosphodiesterase (PDE)	Metabolic Disease
PDE3B-IN-1 is a potent selective PDE3B inhibitor that demonstrates PDE3B inhibitory activity (pIC₅₀ = 6.5) and >300-fold PDE3B/A selectivity .

HY-B0442B

Vardenafil hydrochloride trihydrate 5 Publications Verification	Endogenous Metabolite Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B1209

Etofylline 7-(β-Hydroxyethyl)theophylline	Phosphodiesterase (PDE)	Cardiovascular Disease Inflammation/Immunology
Etofylline (7-(β-Hydroxyethyl) theophylline) is an oral bronchodilator with anti-inflammatory effects. Etofylline inhibits *phosphodiesterase* and prevents the degradation of cAMP (cyclic adenosine monophosphate), leading to smooth muscle relaxation, reducing inflammatory responses and improving respiratory function. Etofylline affects the development of zebrafish embryos .

HY-108974

Drotaverine hydrochloride	Phosphodiesterase (PDE) Calcium Channel	Neurological Disease
Drotaverine hydrochloride is a type *4 cyclic* nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC)** blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine (hydrochloride) exhibits in vivo antispasmodic efficacy without anticholinergic effects.

HY-P2878

Phosphodiesterase I 1 Publications Verification PDE	Phosphodiesterase (PDE)	Neurological Disease Cancer
Phosphodiesterase I (PDE) is an enzyme that can catalyze the hydrolysis of the 3' ring phosphate bond of cyclic nucleotides, and is often used in biochemical research. Phosphodiesterase I acts as an important regulator of signal transduction mediated by the second messenger molecules cAMP and cGMP. According to their specificity to cyclic nucleotides, they can also be divided into different types, such as PDE1-PDE11, which also have certain potential in various diseases .

HY-N6781

Ophiobolin A	Phosphodiesterase (PDE)	Infection Cancer
Ophiobolin A, a fungal metabolite and a phytotoxin, is a potent and irreversibly inhibitor of calmodulin-activated cyclic nucleotide phosphodiesterase, with an IC₅₀ value of 9 μM. Ophiobolin A antimicrobial and anticancer activity .

HY-B0392

(S)-(+)-Rolipram (+)-Rolipram; (S)-Rolipram	Phosphodiesterase (PDE) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
(S)-(+)-Rolipram ((+)-Rolipram) is a cyclic AMP(cAMP)-specific phosphodiesterase 4 (PDE4) inhibitor, with an IC₅₀ of 1100 nM. (S)-(+)-Rolipram can suppresse tumor necrosis factor-alpha (TNFα) production by human mononuclear cells .

HY-12085S

Apremilast-d5 CC-10004-d₅	Phosphodiesterase (PDE) TNF Receptor Apoptosis	Inflammation/Immunology
Apremilast-d₅ is a deuterium labeled Apremilast. Apremilast is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC₅₀ of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC₅₀ of 104 nM .

HY-137672A

2',3'-Cyclic NADP disodium 2',3'-cNADP+; β-Nicotinamide adenine dinucleotide-2',3'-cyclic phosphate	Phosphodiesterase (PDE) Calcium Channel	Neurological Disease
2',3'-Cyclic NADP disodium (2',3'-cNADP+; β-Nicotinamide adenine dinucleotide-2',3'-cyclic phosphate) is a substrate for 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), an enzyme abundant in myelin. It has been used in a coupled enzyme assay to quantify CNP activity. 2',3'-Cyclic NADP disodium (5 μM) increases calcium overload-induced calcium release and prevents calcium-induced swelling in rat brain mitochondria.

HY-108619

Gisadenafil besylate UK 369003-26	Phosphodiesterase (PDE)	Neurological Disease
Gisadenafil besylate (UK 369003-26) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC₅₀ of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP) .

HY-100933

MY-5445 1 Publications Verification	Phosphodiesterase (PDE)	Cardiovascular Disease Inflammation/Immunology Cancer
MY-5445 is a specific inhibitor of the cyclic GMP phosphodiesterase, phosphodiesterase type 5 (PDE5), with a K_i of 1.3 μM. MY-5445 inhibits human platelet aggregation. MY-5445 is a selective modulator of ATP-binding cassette (ABC) transporter ABCG2, with anti-proliferative effect .

HY-B1726

Phenacaine Holocaine	Phosphodiesterase (PDE)	Metabolic Disease
Phenacaine (Holocaine) is a local agent that can suppress or relieve pain. Phenacaine inhibits the specific calmodulin-dependent stimulation of erythrocyte Ca ²⁺-ATPase and cyclic nucleotide phosphodiesterases from brain and heart .

HY-108047

MK-0873	Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology
MK-0873 is a selective phosphodiesterase-4 (PDE4) inhibitor. MK-0873 increases intracellular levels of cyclic adenosine phosphate (cAMP) by inhibiting the activity of the PDE4 enzyme and subsequently activates protein kinase A (PKA). Activated PKA inhibits the activity of inflammatory cells and leads to direct relaxation of airway smooth muscle. MK-0873 can be used in studies of chronic obstructive pulmonary disease (COPD) .

HY-107203

Propentofylline HWA 285	Phosphodiesterase (PDE) Adenosine Receptor	Cardiovascular Disease Neurological Disease Cancer
Propentofylline (HWA 285) is an orally active and brain-penetrant *phosphodiesterase* inhibitor. Propentofylline blocks adenosine reuptake and prevents cyclic nucleotide degradation. Propentofylline can be used for the research of primary degenerative (Alzheimer's) dementia, vascular dementia, cerebral ischemia, acute stroke, and learning and memory disorders .

HY-P2867

Phosphodiesterase II, Bovine Spleen 3′-Exonuclease	Phosphodiesterase (PDE)	Neurological Disease
Phosphodiesterase II (EC 3.1.16.1), namely phosphodiesterase 2, is mainly involved in the hydrolysis of the important second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), and is often used in biochemical research. Phosphodiesterase II is expressed in a variety of tissues, such as the adrenal medulla, brain, heart, platelets, macrophages and endothelial cells, and is involved in the regulation of many different intracellular processes .

HY-165439

Indolidan LY195115	Phosphodiesterase (PDE)	Cardiovascular Disease
Indolidan (LY195115) is an orally active cardiotonic agent and a selective **cyclic nucleotide phosphodiesterase inhibitor. Indolidan has a K_i** of 80 nM for sarcoplasmic reticulum phosphodiesterase (SR-PDE). Indolidan exhibits positive inotropic and vasodilator effects. Indolidan can be used in the research of diseases such as congestive heart failure .

HY-100164

SDZ-MKS 492 MKS 492	Phosphodiesterase (PDE)	Inflammation/Immunology
SDZ-MKS 492 (MKS 492) is a selective inhibitor of cyclic GMP-inhibited phosphodiesterase (type III PDE). SDZ-MKS 492 inhibits antigen- or platelet activating factor (PAF)-induced bronchoconstriction and allergic reactions in guinea pigs and rats .

HY-P2781

3′,5′-Cyclic nucleotide phosphodiesterase	Phosphodiesterase (PDE)	Cardiovascular Disease Neurological Disease Inflammation/Immunology
3′,5′-Cyclic nucleotide phosphodiesterase is a hydrolytic enzyme that degrades cyclic 3', 5' -adenosine monophosphate (cyclic AMP). 3′,5′-Cyclic nucleotide phosphodiesterase is promising for research of cardiovascular diseases, inflammation, central nervous system disorders, and metabolic syndrome .

HY-159857

Gp(2′-5′)Ap sodium Gp(2′-5′)Ap(3′) sodium; 2'5'-GpAp sodium; Guanylyl-(2′→5′)-3′-adenylic acid sodium	Nucleoside Antimetabolite/Analog
Gp(2′-5′)Ap sodium is a linear dinucleotide analog after hydrolysis of cyclic guanosine monophosphate- adenosine monophosphate (2’3’-cGAMP) by phosphodiesterases. Due to its linear conformation, 2’5’GpAp is intended to serve as a negative control for 2’3’-cGAMP in type I IFN induction assays.

HY-B0442AS

Vardenafil-d5 hydrochloride	Endogenous Metabolite Phosphodiesterase (PDE) Isotope-Labeled Compounds	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil-d₅ hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-137108

Sp-8-pCPT-cGMPS	PKA PKG	Neurological Disease
Sp-8-pCPT-cGMPS is a potent cyclic guanosine monophosphate-gated channel agonist and a lipophilic activator of protein kinase G (types I α, I β, and II) and protein kinase A type II with excellent cell membrane permeability and phosphodiesterase stability. Sp-8-pCPT-cGMPS can be used to study the role of cGMP in neural plasticity and synaptic transmission .

HY-115745

Calmodulin antagonist-1	Calmodulin	Cardiovascular Disease
Calmodulin antagonist-1 (A-5) is a calmodulin (CaM) antagonist. Calmodulin antagonist-1 inhibits calmodulin-activated Ca ²⁺-phosphodiesterase (PDE) (IC₅₀=66 μM). Calmodulin antagonist-1 also inhibits trypsin-treated Ca ²⁺-PDE (IC₅₀=560 μM) in a competitive fashion with respect to cyclic GMP .

HY-N1289

Sequosempervirin B	Fungal Phosphodiesterase (PDE)	Infection
Sequosempervirin B, a norlignan isolated from the branches and leaves of Sequoia sempervirens, has antifungal properties. Sequosempervirin B has an inhibitory effect on cyclic AMP phosphodiesterase .

HY-12085R

Apremilast (Standard) CC-10004 (Standard)	Reference Standards Phosphodiesterase (PDE) Apoptosis TNF Receptor	Inflammation/Immunology
Apremilast (Standard) is the analytical standard of Apremilast. This product is intended for research and analytical applications. Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC₅₀ of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC₅₀ of 104 nM .

HY-N8209

(+)-Medioresinol Di-O-β-D-glucopyranoside	Phosphodiesterase (PDE)	Inflammation/Immunology
(+)-Medioresinol Di-O-β-D-glucopyranoside is a lignan glucoside with strong inhibitory activity of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterase .

HY-W011293

DTA 2,4-Disulfamyl-5-trifluoromethylaniline	Phosphodiesterase (PDE)	Others
DTA (2,4-Disulfamyl-5-trifluoromethylaniline) is a **cyclic AMP phosphodiesterase** inhibitor that binds to erythrocyte carbonic anhydrase .

HY-136520A

(R)-Xanthoanthrafil	Phosphodiesterase (PDE)	Metabolic Disease
(R)-Xanthoanthrafil is a phosphodiesterase-5 (PDE5) inhibitor. (R)-Xanthoanthrafil selectively inhibits PDE5, increasing cyclic guanosine monophosphate (cGMP) levels, leading to smooth muscle relaxation and promoting penile erection. (R)-Xanthoanthrafil can be used to study erectile dysfunction .

HY-14841

Gisadenafil UK-369003	Phosphodiesterase (PDE)	Neurological Disease
Gisadenafil (UK-369003) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC₅₀ of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP) .

HY-130786

Denbufylline BRL 30892	Phosphodiesterase (PDE)	Others Inflammation/Immunology
Denbufylline (BRL 30892) is an inhibitor of phosphodiesterase-4 (PDE4). Denbufylline is able to block the degradation of intracellular cAMP (cyclic adenosine phosphate) thereby increasing the level of intracellular cAMP, which helps regulate a variety of cellular functions. Denbufylline can be used in the study of chronic obstructive pulmonary disease (COPD), asthma and other inflammatory diseases .

HY-115269

CK-2289	Phosphodiesterase (PDE)	Cardiovascular Disease
CK-2289 is an inhibitor of type III cyclic 3'5'-adenosine monophosphate *phosphodiesterase* (PDE). CK-2289 can inhibit platelet aggregation and decreases mean arterial blood pressure. CK-2289 can be used for the research of cardiovascular disease, such as congestive heart failure .

HY-107022

BMS-341400	Phosphodiesterase (PDE)	Neurological Disease
BMS-341400 is an orally active selective phosphodiesterase 5 (PDE5) inhibitor with an IC₅₀ value of 0.3 nM. BMS-341400 reduces the degradation of cyclic guanosine monophosphate (cGMP), thereby enhancing nitric oxide (NO)-mediated relaxation of the smooth muscle of the corpus cavernosum and promoting erection. BMS-341400 can be used to study erectile dysfunction.

HY-112631

OPC 33540	Phosphodiesterase (PDE)	Cardiovascular Disease
OPC-33540 is a highly selective and competitive PDE3 inhibitor with IC₅₀ values of 0.32 nM (PDE3A) and 1.5 nM (PDE3B). OPC-33540 exhibits IC₅₀s against PDE1, PDE2, PDE4, PDE5, and PDE7 of 42.9, 52.3, 100.8, 2.5, and 51.3 μM, respectively. OPC-33540 significantly enhances cAMP accumulation in platelets and effectively inhibits thrombin-induced platelet aggregation. OPC-33540 can be used in antithrombotic studies .

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .

HY-134302

8-HA-cAMP 8-Hexylamino-cAMP	PKA	Others
8-HA-cAMP is a membrane-permeable cAMP analogue and an activator of cAMP-dependent protein kinase and PKA I. 8-HA-cAMP exerts metabolic stability towards mammalian cyclic nucleotide-responsive phosphodiesterases .

HY-124176

L-6355	Phosphodiesterase (PDE) Calmodulin	Cardiovascular Disease
L-6355 is an Amiodarone (HY-14187) related compound, which inhibits Ca ²⁺/calmodulin activated **cyclic nucleotide phosphodiesterase with an IC₅₀** value of 0.65 μM. L-6355 is promising for research of antiarrhythmic and antianginal agent .

HY-B0763R

Ibudilast (Standard) KC-404 (Standard); AV-411 (Standard); MN-166 (Standard)	Reference Standards Phosphodiesterase (PDE)	Inflammation/Immunology Cancer
Ibudilast (Standard) is the analytical standard of Ibudilast. This product is intended for research and analytical applications. Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .

HY-P2856

Phosphatidylinositol phosphodiesterase	Endogenous Metabolite	Metabolic Disease
Phosphatidylinositol phosphodiesterase hydrolyzes phosphatidylinositol to diacylglycerols and a mixture of myoinositol 1- and 1, 2-cyclic phosphates .

HY-107203S

Propentofylline-d6 HWA 285-d₆	Isotope-Labeled Compounds Phosphodiesterase (PDE) Adenosine Receptor	Neurological Disease Cancer
Propentofylline-d₆ (HWA 285-d₆) is the deuterium labeled Propentofylline. Propentofylline is an orally active and brain-penetrant *phosphodiesterase* inhibitor. Propentofylline blocks adenosine reuptake and prevents cyclic nucleotide degradation. Propentofylline can be used for the research of primary degenerative (Alzheimer's) dementia, vascular dementia, cerebral ischemia, acute stroke, and learning and memory disorders .

HY-101661

Win 58237	Phosphodiesterase (PDE)	Cardiovascular Disease
Win 58237 is a cyclic nucleotide phosphodiesterase (PDE) inhibitor, with K_i of 170 nM for PDE V, possessing vasorelaxant activity.

HY-32136

1-Phenyl-3,4-dihydroisoquinoline	Phosphodiesterase (PDE)	Inflammation/Immunology
1-Phenyl-3,4-dihydroisoquinoline (compound 13) can inhibit the cyclic nucleotide phosphodiesterase (PDE) .

HY-69317

RS14203 PMNPQ	Phosphodiesterase (PDE)	Others
RS14203 is an orally active type IV cyclic nucleotide phosphodiesterase (PDE IV) inhibitor which can induce emesis .

HY-N8246

2',3'-cUMP sodium Uridine-2', 3'-cyclic monophosphate sodium salt	Others	Others
2',3'-cUMP sodium (Uridine-2', 3'-cyclic monophosphate sodium salt) is a competitive inhibitor of dip-nitrophenyl diphosphate hydrolysis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0442

Vardenafil 5 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-18252

Avanafil 1 Publications Verification TA1790	Cardiovascular Disease Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-B0442A

Vardenafil hydrochloride 5 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil hydrochloride is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-N1938

D(+)-Raffinose pentahydrate D-Raffinose pentahydrate	Polysaccharides other families Classification of Application Fields Other Diseases Plants Endogenous metabolite Disease Research Fields Saccharides Source Classification	Endogenous Metabolite Glucosylceramide Synthase (GCS) Bacterial Phosphodiesterase (PDE) Interleukin Related
D(+)-Raffinose pentahydrate is an orally active inhibitor of LecA (K_d = 32 μM) and GtfC. D(+)-Raffinose pentahydrate reduces cyclic diguanylate (c-di-GMP) by increased activity of a c-di-GMP specific *phosphodiesterase. D(+)-Raffinose pentahydrate interferes with GTF function. D(+)-Raffinose pentahydrate decreases IL-4* and IL-5 mRNA. D(+)-Raffinose pentahydrate exhibits biofilm-inhibitory activity against Pseudomonas aeruginosa and Streptococcus mutans and inhibits allergic airway eosinophilia .

HY-B0442B

Vardenafil hydrochloride trihydrate 5 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-N6781

Ophiobolin A	Infection Microorganisms Classification of Application Fields Terpenoids Sesquiterpenes Disease Research Fields Source Classification	Phosphodiesterase (PDE)
Ophiobolin A, a fungal metabolite and a phytotoxin, is a potent and irreversibly inhibitor of calmodulin-activated cyclic nucleotide phosphodiesterase, with an IC₅₀ value of 9 μM. Ophiobolin A antimicrobial and anticancer activity .

HY-N1289

Sequosempervirin B	Cupressaceae Phenols Polyphenols Plants Sequoia sempervirens (D. Don) Endl. Source Classification	Fungal Phosphodiesterase (PDE)
Sequosempervirin B, a norlignan isolated from the branches and leaves of Sequoia sempervirens, has antifungal properties. Sequosempervirin B has an inhibitory effect on cyclic AMP phosphodiesterase .

HY-N8209

(+)-Medioresinol Di-O-β-D-glucopyranoside	Structural Classification Eucommia ulmoides Oliver Classification of Application Fields Lignans Eucommiaceae Phenylpropanoids Plants Inflammation/Immunology Disease Research Fields Source Classification	Phosphodiesterase (PDE)
(+)-Medioresinol Di-O-β-D-glucopyranoside is a lignan glucoside with strong inhibitory activity of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterase .

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Cardiovascular Disease Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .

HY-N8246

2',3'-cUMP sodium Uridine-2', 3'-cyclic monophosphate sodium salt	Natural Products Microorganisms Source Classification	Others
2',3'-cUMP sodium (Uridine-2', 3'-cyclic monophosphate sodium salt) is a competitive inhibitor of dip-nitrophenyl diphosphate hydrolysis .

HY-124371

Amentoflavone hexaacetate	Flavonoids Viburnaceae Plants Biflavones Viburnum lantana L. Source Classification	Phosphodiesterase (PDE)
Amentoflavone hexaacetate is a 3,5-cyclic nucleotide phosphodiesterase inhibitor with antiplatelet aggregation activity. Amentoflavone hexaacetate can inhibit the aggregation of eluted human platelets induced by ADP or collagen. Amentoflavone hexaacetate can also inhibit the cAMP phosphodiesterase activity in human platelets. Amentoflavone hexaacetate can significantly increase the cAMP level of platelets in the presence of prostaglandin E1. Amentoflavone hexaacetate has anti-angiogenic and anti-metastatic effects .

HY-129665

GS-389 (±)-O,O-Dimethylcoclaurine	Alkaloids Cocculus laurifolius DC. Plants Isoquinoline Alkaloids Menispermaceae Source Classification	Endogenous Metabolite
GS 389 ((±)-O,O-Dimethylcoclaurine) is a tetrahydroisoquinoline. GS-389 inhibites Cyclic AMP and cyclic AMP dependent phosphodiesterases from rat atrial and ventricular tissue. GS-389 relaxes the contraction induced by phenylephrine and high K ⁺ in rat aortic rings .

HY-N14662

Griseolic acid B 7′-Desoxygriseolic acid	Microorganisms Ketones, Aldehydes, Acids Source Classification	Phosphodiesterase (PDE)
Griseolic acid B (7′-Desoxygriseolic acid) has the activity of inhibiting **cyclic adenosine monophosphate (cAMP) phosphodiesterase [EC 3.1.4.17] with an IC₅₀** of 0.16 μM .

HY-B0442C

Vardenafil dihydrochloride	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil dihydrochloride is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM respectively, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^- .

HY-N14663

Griseolic acid C Dihydrodeoxygriseolic acid	Microorganisms Ketones, Aldehydes, Acids Source Classification	Bacterial
Griseolic acid C (Dihydrodeoxygriseolic acid) is an antibiotic. Griseolic acid C can be found in Streptomyces griseoaurantiacus SANK43894. Griseolic acid C has the activity of inhibiting cyclic adenosine monophosphate (cAMP) phosphodiesterase [EC 3.1.4.17] with an IC₅₀ of 0.12 μM (extracted from rat brain) .

HY-B0442CR

Vardenafil dihydrochloride (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442AR

Vardenafil hydrochloride (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite Reference Standards
Vardenafil (hydrochloride) (Standard) is the analytical standard of Vardenafil (hydrochloride). This product is intended for research and analytical applications. Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442R

Vardenafil (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil (Standard) is the analytical standard of Vardenafil. This product is intended for research and analytical applications. Vardenafil is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-W049735R

N,N,O-Tridesmethylvenlafaxine (Standard)	Monophenols Phenols Endogenous metabolite Source Classification	Drug Metabolite Reference Standards Endogenous Metabolite
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442BR

Vardenafil hydrochloride trihydrate (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil (hydrochloride trihydrate) (Standard) is the analytical standard of Vardenafil (hydrochloride trihydrate). This product is intended for research and analytical applications. Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-120241

Reticulol K 251-1	Microorganisms Phenols Polyphenols Source Classification	Phosphodiesterase (PDE)
Reticulol (K 251-1) is an inhibitor of cyclic adenosine 3', 5'-monophosphate phosphodiesterase. Reticulol shows antitumor activity independent with cell cycle arrest or apoptosis. Reticulol inhibits cell growth of murine melanoma cells and human lung tumor cells. Reticulol protects its lung metastasis via the bloodstream by inhibiting the growth of B16F10 melanoma .

HY-18252R

Avanafil (Standard) TA1790 (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-114554

KS 619-1	Structural Classification Microorganisms Xanthones Phenols Source Classification	Phosphodiesterase (PDE) PKC Bacterial
KS 619-1 is a Ca ²⁺/calmodulin-dependent cyclic nucleotide *phosphodiesterase* inhibitor. KS 619-1 exhibits strong inhibitory activity against this enzyme derived from bovine brain and heart, but shows weak inhibitory effects on calmodulin-independent phosphodiesterase and protein kinase C. KS 619-1 displays weak antibacterial activity against Staphylococcus aureus .

HY-113972R

Methyl mycophenolate (Standard)	Structural Classification Monophenols Microorganisms Marine natural products Phenols Marine microorganism	Reference Standards Others
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

Species:	Human (9) Mouse (1)
Tag:	His (8) Tag Free (2) Myc (1) GST (3)
Source:	Sf9 insect cells (5) E. coli (5)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P704128

	PDE4A Protein, Human (sf9, His) DPDE2; phosphodiesterase 4A,cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Human	Sf9 insect cells
	PDE4A Protein, Human (sf9, His) is the recombinant human-derived PDE4A protein, expressed by Sf9 insect cells, with C-His tag.

HY-P71591

	cGB-PDE Protein, Mouse (Myc, His) Pde5a; Pde5; cGMP-specific 3',5'-cyclic phosphodiesterase; EC 3.1.4.35; cGMP-binding cGMP-specific phosphodiesterase; CGB-PDE	Mouse	E. coli
	cGB-PDE protein regulates signal transduction by specifically hydrolyzing cto 5'-GMP, thereby controlling the intracellular concentration of cyclic nucleotides, particularly nitric-oxide-generated cGMP. cGB-PDE Protein, Mouse (Myc, His) is the recombinant mouse-derived cGB-PDE protein, expressed by E. coli , with N-His, C-Myc labeled tag.

HY-P74647

	PDE2A Protein, Human (sf9, His) cGMP-dependent 3',5'-cyclic phosphodiesterase; CGS-PDE; PDE2A	Human	Sf9 insect cells
	PDE2A is a cGMP-activated cyclic nucleotide phosphodiesterase that exhibits dual specificity for the second messengers cAMP and cGMP, key regulators in various physiological processes. PDE2A exhibits higher efficiency by covering cAMP and plays an important role in cell growth and migration. PDE2A Protein, Human (sf9, His) is the recombinant human-derived PDE2A protein, expressed by Sf9 insect cells , with C-His labeled tag.

HY-P75963

	PDE9A Protein, Human (His) High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A; PDE9A	Human	E. coli
	PDE9A is a phosphodiesterase that uniquely hydrolyzes second messengers with unparalleled specificity, particularly in the regulation of natriuretic peptide-dependent signaling in the heart, which is critical for the control of cardiac hypertrophy. Its specificity rules out effects on nitric oxide-dependent signaling in the heart. PDE9A Protein, Human (His) is the recombinant human-derived PDE9A protein, expressed by E. coli , with N-His labeled tag.

HY-P701960

	PDE4D Protein, Human PDE4D; cAMP-specific 3'; 5'-cyclic phosphodiesterase 4D; DPDE3; PDE43	Human	E. coli
	PDE4D (Phosphodiesterase 4D) protein, as a hydrolytic enzyme, degrades the second messenger cAMP, a crucial regulator in various physiological processes. Its enzymatic activity in breaking down cAMP underscores PDE4D's pivotal role in modulating cellular signaling cascades, maintaining the intricate balance of intracellular communication mediated by this critical second messenger. PDE4D Protein, Human is the recombinant human-derived PDE4D protein, expressed by E. coli , with tag free.

HY-P701961

	PDE4D Protein, Human (His) PDE4D; cAMP-specific 3'; 5'-cyclic phosphodiesterase 4D; DPDE3; PDE43	Human	E. coli
	PDE4D (Phosphodiesterase 4D) protein, as a hydrolytic enzyme, degrades the second messenger cAMP, a crucial regulator in various physiological processes. Its enzymatic activity in breaking down cAMP underscores PDE4D's pivotal role in modulating cellular signaling cascades, maintaining the intricate balance of intracellular communication mediated by this critical second messenger. PDE4D Protein, Human (His) is the recombinant human-derived PDE4D protein, expressed by E. coli , with N-6*His labeled tag.

HY-P75961

	PDE3A Protein, Human (sf9, His-GST) cGMP-inhibited 3',5'-cyclic phosphodiesterase A; CGI-PDE A; PDE3A	Human	Sf9 insect cells
	PDE3A protein, a cyclic nucleotide phosphodiesterase, targets cAMP, cGMP, and cUMP, crucial in diverse physiological processes. In an E2/17beta-estradiol-induced pro-apoptotic pathway, E2 stabilizes the PDE3A/SLFN12 complex, leading to SLFN12 dephosphorylation and activating its pro-apoptotic ribonuclease activity. This pathway is implicated in tissues with high E2 concentrations, potentially contributing to processes like placenta remodeling. PDE3A Protein, Human (sf9, His-GST) is the recombinant human-derived PDE3A protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P75962

	PDE9A Protein, Human (sf9, His-GST) High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A; PDE9A	Human	Sf9 insect cells
	PDE9A is a phosphodiesterase that uniquely hydrolyzes second messengers with unparalleled specificity, particularly in the regulation of natriuretic peptide-dependent signaling in the heart, which is critical for the control of cardiac hypertrophy. Its specificity rules out effects on nitric oxide-dependent signaling in the heart. PDE9A Protein, Human (sf9, His-GST) is the recombinant human-derived PDE9A protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P703577

	PDE7A1 Protein, Human High affinity 3',5'-cyclic-AMP phosphodiesterase 7A; HCP1; TM22; cAMP-specific phosphodiesterase 7A; PDE7A; Homo sapiens; Human; Hydrolase; 3.1.4.53	Human	E. coli
	PDE7A1 Protein, Human is the recombinant human-derived PDE7A1, expressed by E. coli , with tag Free labeled tag. ,

HY-P75960

	PDE1B Protein, Human (sf9, His-GST) Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B; Cam-PDE 1B; PDE1B1; PDES1B	Human	Sf9 insect cells
	PDE1B protein, a cyclic nucleotide phosphodiesterase, displays dual specificity for cAMP and cGMP, essential second messengers in physiological processes. Preferring cGMP as a substrate, PDE1B fine-tunes cellular responses to cyclic nucleotide signaling. Its dual specificity underscores its regulatory role in diverse physiological pathways. PDE1B Protein, Human (sf9, His-GST) is the recombinant human-derived PDE1B protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-12085S

Apremilast-d5
Apremilast-d₅ is a deuterium labeled Apremilast. Apremilast is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC₅₀ of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC₅₀ of 104 nM .

HY-B0442AS

Vardenafil-d5 hydrochloride

Vardenafil-d₅ hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-107203S

Propentofylline-d6

Propentofylline-d₆ (HWA 285-d₆) is the deuterium labeled Propentofylline. Propentofylline is an orally active and brain-penetrant phosphodiesterase inhibitor. Propentofylline blocks adenosine reuptake and prevents cyclic nucleotide degradation. Propentofylline can be used for the research of primary degenerative (Alzheimer's) dementia, vascular dementia, cerebral ischemia, acute stroke, and learning and memory disorders .

HY-108974S

Drotaverine-d10 hydrochloride

Drotaverine-d₁₀ (hydrochloride) is the deuterium labeled Drotaverine hydrochloride. Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine hydrochloride exhibits in vivo antispasmodic efficacy without anticholinergic effects .

HY-B0442S

Vardenafil-d5

Vardenafil-d₅ is deuterium labeled Vardenafil. Vardenafil is a selective, orally active, potent inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM). Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction .

HY-12085S1

Apremilast-d8
Apremilast-d₈ (CC-10004-d₈) is deuterium labeled Apremilast. Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC₅₀ of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC₅₀ of 104 nM .

HY-12085S3

Apremilast-d3
Apremilast-d₃ (CC-10004-d₃) is deuterium labeled Apremilast. Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC₅₀ of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC₅₀ of 104 nM .

HY-B0763S1

Ibudilast-d7

Ibudilast-d₇ is the deuterium labeled Ibudilast. Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .

HY-B0763S

Ibudilast-d3

Ibudilast-d₃ (KC-404-d₃) is the deuterium labeled Ibudilast. Ibudilast (KC-404) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .

HY-B0763S2

Ibudilast-d7-1

Ibudilast-d₇-1 is the deuterium labeled Ibudilast . Ibudilast (KC-404;AV-411;MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .

HY-18252S3

Avanafil-13C5

Avanafil- ¹³C₅ (TA1790- ¹³C₅) is ¹³C labeled Avanafil. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252S1

Avanafil-13C5,15N,d2

Avanafil- ¹³C₅, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

Host:	Rabbit (2)
Reactivity:	Human (2) Rat (1) Mouse (1)
Application:	IHC-P (1) WB (2) FC (1)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (2) Recombinant (2)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P87358

	PDE10A Antibody (YA7041) 5''-cyclic phosphodiesterase 10A antibody; cAMP and cAMP inhibited cGMP 3'5' cyclic phosphodiesterase 10A antibody; cAMP and cAMP-inhibited cGMP 3'' antibody; FLJ11894 antibody; HSPDE 10A antibody; HSPDE10A antibody; PDE 10A antibody; PDE10_HUMAN antibody; Pde10a antibody; phosphodiesterase 10A antibody	WB, IHC-P, FC	Human, Mouse, Rat
	PDE10A Antibody (YA7041) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PDE10A.

HY-P81969

	PDE4D Antibody (YA1714) cAMP-specific 3' ; 5' -cyclic phosphodiesterase 4D; DPDE3; PDE43; PDE4D; DPDE3	WB	Human
	PDE4D Antibody (YA1714) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PDE4D.